{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:16:14Z","timestamp":1788297374622,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.7759\/cureus.115610","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:33:36Z","timestamp":1788294816000},"source":"Crossref","is-referenced-by-count":0,"title":["From Multiple Treatment Failures to Functional Improvement With Lower-Sodium Oxybate in Idiopathic Hypersomnia: A Case Report"],"prefix":"10.7759","author":[{"given":"Binh","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"International Classification of Sleep Disorders (ICSD) (2023). (2026). https.\/\/aasm.org\/clinical-resources\/international-classification-sleep-disorders\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2017.03.009","article-title":"Idiopathic hypersomnia","volume":"12","author":"Trotti LM","year":"2017","unstructured":"Trotti LM. Idiopathic hypersomnia. Sleep Med Clin. 2017, 12:331-344. 10.1016\/j.jsmc.2017.03.009","journal-title":"Sleep Med Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/NSS.S396641","article-title":"Impairment in functioning and quality of life in patients with idiopathic hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE)","volume":"15","author":"Stevens J","year":"2023","unstructured":"Stevens J, Schneider LD, Husain AM, Ito D, Fuller DS, Zee PC, Macfadden W. Impairment in functioning and quality of life in patients with idiopathic hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE). Nat Sci Sleep. 2023, 15:593-606. 10.2147\/NSS.S396641","journal-title":"Nat Sci Sleep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.2922","article-title":"Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia","volume":"9","author":"Trotti LM","year":"2013","unstructured":"Trotti LM, Staab BA, Rye DB. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med. 2013, 9:789-795. 10.5664\/jcsm.2922","journal-title":"J Clin Sleep Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9328","article-title":"Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline","volume":"17","author":"Maski K","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, Watson NF. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021, 17:1881-1893. 10.5664\/jcsm.9328","journal-title":"J Clin Sleep Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00368-9","article-title":"Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study","volume":"21","author":"Dauvilliers Y","year":"2022","unstructured":"Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al.. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022, 21:53-65. 10.1016\/S1474-4422(21)00368-9","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/NSS.S369122","article-title":"Efficacy and safety of lower-sodium oxybate in an open-label titration period of a phase 3 clinical study in adults with idiopathic hypersomnia","volume":"14","author":"Thorpy MJ","year":"2022","unstructured":"Thorpy MJ, Arnulf I, Foldvary-Schaefer N, et al.. Efficacy and safety of lower-sodium oxybate in an open-label titration period of a phase 3 clinical study in adults with idiopathic hypersomnia. Nat Sci Sleep. 2022, 14:1901-1917. 10.2147\/NSS.S369122","journal-title":"Nat Sci Sleep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns MW","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991, 14:540-545. 10.1093\/sleep\/14.6.540","journal-title":"Sleep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12201","article-title":"Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study","volume":"24","author":"Mayer G","year":"2015","unstructured":"Mayer G, Benes H, Young P, Bitterlich M, Rodenbeck A. Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study. J Sleep Res. 2015, 24:74-81. 10.1111\/jsr.12201","journal-title":"J Sleep Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/30.10.1274","article-title":"Idiopathic hypersomnia: a study of 77 cases","volume":"30","author":"Anderson KN","year":"2007","unstructured":"Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM. Idiopathic hypersomnia: a study of 77 cases. Sleep. 2007, 30:1274-1281. 10.1093\/sleep\/30.10.1274","journal-title":"Sleep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.248120","article-title":"Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor","volume":"366","author":"Baladi MG","year":"2018","unstructured":"Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018, 366:367-376. 10.1124\/jpet.118.248120","journal-title":"J Pharmacol Exp Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9513-5","article-title":"Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults","volume":"44","author":"Li L","year":"2017","unstructured":"Li L, Wang Y, Uppoor RS, Mehta MU, Farchione T, Mathis MV, Zhu H. Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults. J Pharmacokinet Pharmacodyn. 2017, 44:245-262. 10.1007\/s10928-017-9513-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000221","article-title":"Hemodynamic profiles and tolerability of modafinil in the treatment of postural tachycardia syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Kpaeyeh J Jr","year":"2014","unstructured":"Kpaeyeh J Jr, Mar PL, Raj V, et al.. Hemodynamic profiles and tolerability of modafinil in the treatment of postural tachycardia syndrome: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2014, 34:738-741. 10.1097\/JCP.0000000000000221","journal-title":"J Clin Psychopharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813751","article-title":"Psychosis with methylphenidate or amphetamine in patients with ADHD","volume":"380","author":"Moran LV","year":"2019","unstructured":"Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019, 380:1128-1138. 10.1056\/NEJMoa1813751","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0382-z","article-title":"Neurophysiological signature of gamma-hydroxybutyrate augmented sleep in male healthy volunteers may reflect biomimetic sleep enhancement: a randomized controlled trial","volume":"44","author":"Dornbierer DA","year":"2019","unstructured":"Dornbierer DA, Baur DM, Stucky B, et al.. Neurophysiological signature of gamma-hydroxybutyrate augmented sleep in male healthy volunteers may reflect biomimetic sleep enhancement: a randomized controlled trial. Neuropsychopharmacology. 2019, 44:1985-1993. 10.1038\/s41386-019-0382-z","journal-title":"Neuropsychopharmacology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.10698","article-title":"Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia","volume":"19","author":"Morse AM","year":"2023","unstructured":"Morse AM, Dauvilliers Y, Arnulf I, et al.. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. J Clin Sleep Med. 2023, 19:1811-1822. 10.5664\/jcsm.10698","journal-title":"J Clin Sleep Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/529155-from-multiple-treatment-failures-to-functional-improvement-with-lower-sodium-oxybate-in-idiopathic-hypersomnia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:33:36Z","timestamp":1788294816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/529155-from-multiple-treatment-failures-to-functional-improvement-with-lower-sodium-oxybate-in-idiopathic-hypersomnia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.115610","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}